Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 127 of the 143 references it cites were found in a registry or an index; 5 of the 101 sources its claims cite were checked for support.

Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling

Open access
Choi, Go-Wun, Lee, Yong-Bok, Cho, Hea-Young · 2019 · Pharmaceutics

Abstract

Extrapolation of pharmacokinetic (PK) parameters from in vitro or in vivo animal to human is one of the main tasks in the drug development process. Translational approaches provide evidence for go or no-go decision-making during drug discovery and the development process, and the prediction of human PKs prior to the first-in-human clinical trials. In vitro-in vivo extrapolation and allometric scaling are the choice of method for projection to human situations. Although these methods are useful tools for the estimation of PK parameters, it is a challenge to apply these methods since underlying biochemical, mathematical, physiological, and background knowledge of PKs are required. In addition, it is difficult to select an appropriate methodology depending on the data available. Therefore, this review covers the principles of PK parameters pertaining to the clearance, volume of distribution, elimination half-life, absorption rate constant, and prediction method from the original idea to recently developed models in order to introduce optimal models for the prediction of PK parameters.

Overview

CoChat Summary

## TL;DR

This review summarizes in vitro-in vivo extrapolation (IVIVE) and allometric scaling (AS) approaches for predicting human pharmacokinetic parameters from non-clinical data. It argues that both methods are useful, but accuracy depends heavily on choosing the right model and correction factors such as protein binding, blood flow, and species-specific scaling terms.

## Key findings

  • For clearance prediction, AS is “a powerful method” for using non-clinical data, but simple AS alone is often insufficient; the review highlights several refinements such as the rule of exponent (ROE), liver blood flow correction, protein binding correction, QSAR, FCIM, and multiexponential allometric scaling.
  • The ROE guidance stated in the paper is: exponent 0.55–0.7 → simple AS; 0.71–1.0 → CL × MLP method; >1.0 → CL × BW method.
  • In IVIVE, adding correction factors can improve prediction: Lave et al. reported that correcting clearance with in vitro metabolic rates significantly improved prediction of human CL for 10 extensively metabolized drugs; Chiou et al. reported improved prediction for 15 extensively metabolized drugs when protein binding was considered.
  • For volume of distribution, the paper reports that Vd is generally well correlated with body weight, with exponents around 1, usually between 0.8 and 1.1; Mahmood and Balian reported average simple-AS exponents of 0.89 (3 species) and 0.90 (2 species).

## Methods

  • Narrative review of methods for predicting human PK parameters from non-clinical data, focused on clearance, volume of distribution, elimination half-life, and absorption-related parameters.
  • Synthesizes prior studies using in vitro systems (e.g., human liver microsomes, hepatocytes, recombinant CYP systems) and animal PK data across species for IVIVE and AS.
  • Compares empirical and physiologically based analyses, including well-stirred and parallel-tube hepatic clearance models, correction-factor approaches, and multiple AS variants.

## Limitations

  • The paper states that IVIVE requires substantial PK knowledge, complex mathematical equations, and is expensive and time-consuming.
  • The paper states that AS is empirical and can perform poorly for drugs with high protein binding, extensive active renal secretion, transport processes, or species-specific binding/distribution.
  • Evident from the text: this is a review article rather than a new experimental study, so its conclusions depend on the quality and scope of the cited literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics11040168

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The perfusion model including one reservoir and one clearing organ. In this model, Q refers to the rate of perfusate or blood flow. Cin is the drug concentration in the artery entering the reservoir and clearing organ. Cout denotes the drug concentration in veins leaving the clearing organ and entering the reservoir, which is a non-clearing organ. VE and VR indicate the volume of clearing organ and reservoir, respectively. The elimination process is followed by first-order kinetics and its elimination constant is represented by kel. CE is the drug concentration in the clearing organ.
Figure 1 The perfusion model including one reservoir and one clearing organ. In this model, Q refers to the rate of perfusate or blood flow. Cin is the drug concentration in the artery entering the reservoir and clearing organ. Cout denotes the drug concentration in veins leaving the clearing organ and entering the reservoir, which is a non-clearing organ. VE and VR indicate the volume of clearing organ and reservoir, respectively. The elimination process is followed by first-order kinetics and its elimination constant is represented by kel. CE is the drug concentration in the clearing organ.CC BY · PubMed Central
Figure 2 The scheme of the overall in vitro-in vivo extrapolation (IVIVE) process using human liver microsomes or recombinant human cytochrome P450 (CYP) system. MPPGL refers to the microsomal protein per gram of liver.
Figure 2 The scheme of the overall in vitro-in vivo extrapolation (IVIVE) process using human liver microsomes or recombinant human cytochrome P450 (CYP) system. MPPGL refers to the microsomal protein per gram of liver.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 6 Not valid · 80 Not checked · 36 Own results and interpretations

72 more claims

Create a free account to see all 127 claims and to verify the 14 references still open.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 31

Create a free account to see these claims.

Citations

Cites

Show all 143 references

Research works printed but not linked: 4

  1. Shargel, L., Andrew, B.C., and Wu-Pong, S. (2016). Applied Biopharmaceutics & Pharmacokinetics, Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division. [7th ed.].
  2. Weiner, J.G.D. (2016). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press. [5th ed.].
  3. Carlile, 1997, Scaling factors to relate drug metabolic clearance in hepatic microsome, isolated hepatocytes, and the intact liver, Drug Metab. Dispos., 25, 903
  4. Kenyon, E.M. (2012). Computational Toxicology: Methods in Molecular Biology, Humana Press.

Cited by

See all 79

Metadata

Authors
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y.
Affiliations
  • CHA University (KR)
  • Chonnam National University (KR)
Corresponding author
Cho, Hea-Young
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2019-04-05
Volume
11
Issue
4
Pages
168
ISSN
1999-4923 (ISSN-L)
OpenAlex
W2930584951
Cited by
79
References
143
Citations by year
2026: 9 · 2025: 11 · 2024: 14 · 2023: 7 · 2022: 14 · 2021: 11 · 2020: 12 · 2019: 1
FWCI
2.50
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
in vitro-in vivo extrapolation, allometric scaling, human pharmacokinetic prediction, drug development, clearance, volume of distribution, elimination half-life, absorption rate constant, translational toxicology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. https://app.cochat.ai/papers/10.3390/pharmaceutics11040168
The paper
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019). Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11040168

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.